Guardian Pharmacy Services Earnings Call Transcripts
Fiscal Year 2026
-
Q3 growth in residents, prescriptions, gross profit and Adjusted EBITDA drove higher FY 2026 guidance. Improved reimbursement and expansion support results, while IRA price reductions weighed on reported revenue.
-
The company leverages a unique local autonomy model and strong financial position to drive growth through organic expansion, acquisitions, and greenfield startups. Despite IRA-related revenue headwinds, margins remain stable, and recent strategic moves, including a file buy acquisition and geographic expansion, position the business for continued success.
-
Revenue grew 2% year-over-year in Q2 2026, with adjusted EBITDA up 19% and net income reaching $22.1 million. Full-year guidance was raised, reflecting strong organic growth and disciplined M&A, while IRA-related pricing reductions continue to impact reported revenue.
-
Delivered a strong quarter, raised annual guidance, and expects high single-digit organic growth, with additional upside from M&A. Maintains a strong balance sheet, leverages scale for profitability, and sees significant opportunity for expansion in the fragmented assisted living pharmacy market.
-
Solid Q1 results with 2% revenue growth and 19% gross profit increase despite IRA headwinds. Updated adjusted EBITDA guidance to $123–$127 million, maintained revenue outlook, and continued robust M&A activity.
-
Strong Q4 momentum was driven by vaccine clinics, acquisitions, and operational optimization. Guidance was raised on robust vaccine performance, with IRA headwinds expected to diminish. Growth is supported by demographic trends, M&A, and innovative clinical programs, while strong cash flow enables continued expansion.
-
A leading assisted living pharmacy provider is leveraging organic growth, disciplined M&A, and a tech-enabled service model to expand its 13% market share. Strong financials, high adoption rates, and proactive regulatory engagement position it for continued growth amid favorable demographic trends.
-
A leading long-term care pharmacy provider for assisted living facilities, the company leverages technology, data analytics, and a disciplined growth strategy to expand its 13% market share. Despite regulatory headwinds from the Inflation Reduction Act, it projects continued EBITDA growth and strong cash flow, supported by organic expansion and targeted M&A.
Fiscal Year 2025
-
Q4 and full-year 2025 results exceeded expectations, with 18% revenue growth and 27% adjusted EBITDA growth year-over-year. Raised 2026 EBITDA guidance to $120–$124 million, maintaining strong cash flow and robust M&A pipeline amid industry changes.
-
The conference highlighted a focused growth strategy in assisted living, leveraging tech-enabled services, data analytics, and targeted acquisitions to expand market share. Despite regulatory headwinds from the IRA, operational efficiencies and direct payer relationships are expected to sustain profitability. Adjacent markets like PACE and hospice offer additional growth opportunities.
-
Achieved 20% revenue growth and 19% adjusted EBITDA growth year-over-year, raising full-year guidance for both metrics. Recent acquisitions and organic growth drove results, with steady margins and strong cash generation supporting ongoing expansion.
-
A specialized pharmacy provider for assisted living is leveraging its market leadership, scale, and tech-enabled services to drive double-digit growth through organic expansion and M&A. Strategic focus on reimbursement, regulatory mitigation, and adjacent markets supports a strong financial profile and differentiates it from legacy competitors.
-
Q2 2025 saw double-digit growth in revenue, resident count, and adjusted EBITDA, with strong organic and acquisition-driven expansion. Guidance for full-year revenue and EBITDA was raised, while policy risks from the IRA and PBM negotiations are being proactively managed.
-
Q1 2025 saw 20% revenue growth and 16% higher Adjusted EBITDA, driven by organic expansion and acquisitions. Guidance was raised to the upper end of the revenue range, with integration costs impacting Q1 but future margin improvements expected as new pharmacies scale.
-
A leading assisted living pharmacy provider reported strong Q4 and full-year growth, driven by organic expansion, M&A, and successful vaccine clinics. With 12% market share, stable margins, and energized employee ownership, the company projects continued growth and margin improvement in 2025.
Fiscal Year 2024
-
Q4 and full-year 2024 saw double-digit revenue and EBITDA growth, driven by organic expansion, acquisitions, and improved vaccine clinic profitability. Guidance for 2025 projects continued high single-digit growth, steady margins, and robust M&A activity, with proactive risk management around the Inflation Reduction Act.
-
A leading long-term care pharmacy provider is leveraging its 12% assisted living market share and tech-enabled services to drive organic and M&A-fueled growth. Legislative and commercial strategies are in place to address IRA-related reimbursement headwinds, while robust data analytics underpin operational efficiency and value for partners.
-
Third quarter revenue rose 20% year-over-year to $314 million, with adjusted EBITDA also up 20%. Resident count increased 12%, and the Heartland acquisition is progressing well. Guidance for 2024 projects $1.205–$1.215 billion in revenue and $86.5–$87 million in adjusted EBITDA.